{
  "id": 1241561,
  "title": "Pennant group chief clinical officer sells $53,699 in stock",
  "url": "https://urgent.news/2026/08/16/pennant-group-chief-clinical-officer-sells-53-699-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-16T09:01:13.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/pennant-group-chief-clinical-officer-sells-53699-in-stock-93CH-4861948"
  },
  "original_language": "en",
  "account": null,
  "summary": "Pennant Group, Inc. (NASDAQ:PNTG) Chief Clinical Officer Jason Paul Steik sold 1,394 shares of the company's common stock on August 6, 2026, at a price of $38.522 per share, totaling $53,699. This sale comes as PNTG shares are trading near $39.32, marking a strong 55.66% return over the past year and a 39.68% gain year-to-date. Following the sale, Steik directly holds 15,106 shares of Pennant Group, Inc. common stock. The information was disclosed in a Form 4 filing with the Securities and Exchange Commission. Analysts note that the stock appears overvalued, trading at a P/E ratio of 42.92. Meanwhile, The Pennant Group reported its second-quarter 2026 financial results, surpassing Wall Street expectations with adjusted earnings of $0.36 per share on revenue of $298.0 million. This marks a significant revenue increase of 35.8% compared to the same period last year, with adjusted EBITDA rising by 48.2%. In response, Wells Fargo raised its price target for The Pennant Group to $46 from $45, maintaining an Overweight rating.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Pennant group CEO Brent Guerisoli sells $165,066 in shares",
        "url": "https://urgent.news/2026/08/16/pennant-group-ceo-brent-guerisoli-sells-165-066-in-shares",
        "published": "2026-08-16T09:01:15.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}